TTHX1114(NM141)
DrugTTHX1114
NCT Number: NCT04676737
Open label, single-treatment, with a concurrent non-treatment control
Looking for future studies?
Notify Me18 year and older
All sexes
Interventional
Phase 2
Trefoil Investigational Site 124, Long Beach, California, United States
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Key Inclusion Criteria:
Key Exclusion Criteria:
TTHX1114
Time frame: Day 28
Change from baseline
Trefoil Therapeutics, Inc.
Industry
Phase 2 Study To Determine the Safety and Efficacy of TTHX1114(NM141) on the Regeneration and Migration of Corneal Endothelial Cells in Patients Undergoing DWEK/DSO
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07729137
Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Corneal Diseases
Menlo Park, California, United States
View Trial DetailsNCT05275972
Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Corneal Diseases
Palo Alto, California, United States
View Trial DetailsNCT05636579
Bullous Keratopathy, Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Mexico City, Mexico
View Trial DetailsNCT06881771
Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Corneal Diseases
London, United Kingdom
View Trial Details